Tonocard - Tocainide

Tonocard (Tocainide). AstraZeneca. US Prescribing informaticn, September 2000. 

Tobi 65 Tobradex 82 Tobramycin 65, 82 Tobrex 65 Tocainide 65 Tofianil 41 Tolcapone 65 ToleSn 65 Tolmetin 65 Tonocard 65 Topamax 66 Topiramate 66 Toprol XL 48 Toradd 43 Tornalate 18 Torsemide 66... 

Tocainide is used for suppressing symptoms of ventricular arrhythmia and tachycardia, and for premature cardiac contractions. A synonym of this drug is tonocard. 

Tocainide (Tonocard) is an orally effective antiarrhyth-mic agent with close structural similarities to lidocaine. 

ADIS Editors and Consultants. Tocainide (Tonocard) a review of its pharmacological properties and therapeutic efficacy. Curr Ther 1984 July 17. 

Tocainide, proprietary name Tonocard, has electrophysiolog-ical properties similar to lidocaine. It is useful in the management of ventricular arrhythmias typified by a prolonged QT interval. Tocainide has the advantage over lidocaine in that it can be taken orally, and it has a relatively long half-life (13 to 16 hours). Optimal response to tocainide... 

Tocainide (Tonocard) Decreases automaticity of AV node and ectopic foci. Shortens refractory period in atrium, AV node, and ventricle. Prolongs refractory period in accessory pathway. (1 ff Dizziness, tremor, paresthesias, nausea, vomiting, pulmonary fibrosis, bone marrow supression. 

Tocainide (Tonocard) (Fig. 26.11) is an a-methyl analogue structurally related to monoethylglycinexylide, the active metabolite of lidocaine, which possesses very similar electrophysiologic effects to lidocaine. In contrast to lidocaine, tocainide is orally active, and its oral absorption is excellent. Like lidocaine, it usually is reserved for the treatment of ventricular arrhythmias. The a-methyl group is believed to slow the rate of metabolism and, thereby, to contribute to oral activity. The plasma half-life of tocainide is approximately 12 hours, and nearly 50% of the drug may be excreted unchanged in the urine. Adverse effects associated with tocainide are like those observed with lidocaine—specifically, gastrointestinal disturbances and central nervous system effects. 

---